WGS · GeneDx Holdings Corp.

Track WGS — free

$72.30 -3.49 (-4.60%) At close · Sep 30

Russell 2000 member Rebalance outlook locked

Market Cap

$2.64B

29.82M

Volume · Sep 30 905.17K Avg daily vol (3M) 724.77K

Up next

Next earnings call

Nov 2, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 3, 2026

Q2 2026 earnings call transcript

call held Aug 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$454.43M

Trailing 12 months

Net income (TTM)

−$106.36M

Trailing 12 months

Revenue growth YoY

+11.4%

Year over year

Operating margin

-20.3%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-2.9%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$35.71M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-0.1%

Year over year · fewer shares

Price change (1Y)

-33.5%

Trailing year

Short interest

19.7%

Latest settlement · 12.1 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 3, 2026

Q2 FY26

TL;DR. GeneDx reported Q2 2026 revenue of $114.4M (up 11% YoY) and exome/genome volume of 30,785 (up 32% YoY), returned to adjusted net income of $0.4M one quarter ahead of plan, but reaffirmed full-year revenue guidance of $475–$490M with ARR flat and meaningful uplift pushed to 2027 as the company invests in revenue cycle management and collections.

Bullish

+ Returned to profitability one quarter ahead of plan with $0.4M adjusted net income
+ Exome and genome volume grew 32% YoY to a record 30,785 tests
+ Q2 exome and genome revenue grew 17% YoY to $100.3M, exceeding guide
+ Commercial genome coverage expanded from 47% to 87% of lives via Carelon, opening up to 56M lives
+ Pro-forma liquidity strengthened to ~$188M with $50M Blackstone debt expansion and equity investment

Bearish

− Revenue (11% YoY) is growing materially slower than exome/genome volume (32% YoY) due to mix shift to lower-reimbursed genome
− GAAP net loss of $17.7M despite adjusted profitability, including certain litigation reserves
− Whole genome COGS is nearly 2x exome COGS, pressuring gross margin until 2027 step improvements
− Full-year 2026 revenue guidance only reaffirmed at $475–$490M with meaningful collection rate uplift deferred to 2027

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Sell

50 / 200-day cross Golden cross

Price vs 200-day avg −9%

below

Price vs 50-day avg −11%

below

RSI (14) 35

neutral

MACD trend Negative

52-week position 28%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return −15%

trailing

6-month return +20%

trailing

YTD return −44%

this year

Relative strength +8%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) Golden cross

50d $81 › 200d $79 — 50d above 200d

Institutional flow Distributing

-8% holders QoQ · +54 funds added

Insider flow Distributing

Net -$1.8M over 90 days · 100% sells

Short interest Falling

19.73% of float · ▼ -1.9% MoM · 12.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

227 holders — mid 3-yr range

Squeeze score 75

high risk · 0–100

Fundamentals

Excellent

Revenue growth +40%

Y/Y

Gross margin 70%

expanding

EPS growth +62%

Y/Y

Free cash flow $14.3M

Balance sheet $52.3M

net cash

Quant / Vol

risk profile

Very High

Volatility 85%

annualized · 1-yr

Max drawdown −79%

past year

ATR 8.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 4 of last 4

Latest guidance · from the 8-K filed Aug 3, 2026

Full Year 2026 Guidance

Revenue Initiated $475M – $490M

prior FY $427.54M midpoint +12.9% Y/Y

Exome and genome revenue Initiated at least 20%

Adjusted gross margin Non-GAAP Initiated 70%

Third Quarter 2026 Guidance

Revenue Initiated $122M – $124M

prior qtr $114.44M midpoint +7.5% QoQ

Exome and genome revenue Initiated $110M – $112M

Adjusted gross margin Non-GAAP Initiated 70%

Guided vs delivered · last 4 settled

Full year 2024 revenues full year 2024

guided $235M – $245M

guided $235M – $245M $305.45M Beat +27.3%

Revenues full year 2023

guided $187M – $192M

guided $187M – $192M $202.57M Beat +6.9%

Revenue full year 2022

guided $215M – $225M

guided $215M – $225M $234.69M Beat +6.7%

Revenue full-year 2021

guided $201M – $204M

guided $201M – $204M $212.2M Beat +4.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

Golden cross Bullish

Price vs 200-day avg

−9% Bearish

Price vs 50-day avg

−11% Bearish

RSI (14)

35 Neutral

MACD trend

Negative Bearish

52-week position

28% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) Golden cross

50d $81 › 200d $79 — 50d above 200d

Institutional flow Distributing

-8% holders QoQ · +54 funds added

Insider flow Distributing

Net -$1.8M over 90 days · 100% sells

Short interest Falling

19.73% of float · ▼ -1.9% MoM · 12.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

227 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $35 Now $72 · 28% Range high $168

vs 200-day avg -9% vs 50-day avg -11% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
WGS GeneDx Holdings Corp. this stock	$2.64B	-44.4%	+40.0%	—	19.7%
TMO Thermo Fisher Scientific Inc.	$249.58B	+16.5%	+14.5%	36.3	1.4%
DHR Danaher Corp /De/	$155.42B	-3.2%	+8.5%	39.2	1.2%
NTRA Natera, Inc.	$59.47B	+80.4%	-2.8%	—	3.3%
A Agilent Technologies, Inc.	$48.90B	+26.6%	+6.4%	34.2	1.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

227

% held: 109.7%
Net QoQ: +849.3K sh
Top holder: Corvex Management LP

Held Float

View

Held by Funds

Fund positions

216

View

Short & Settlement

Short Interest Falling

Shares short

5.9M

Days to cover: 12.1d
Change: -116.5K sh

View

Short Volume

Short vol %

64%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

118

Value: $9.9K
As of: Sep 11, 2026

View

Off-Exchange

Off-exchange %

45.2%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.8M

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

$427.5M

Net income (FY): $-21.0M
EPS diluted: $-0.73

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 8, 2026
This year: 16

View

Proposed Sales

Value

$929.9K

Shares: 9.4K
Filed: Feb 2, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 8, 2026

View

Performance

	5D	20D	120D	MTD	YTD
WGS	-15.1%	-14.8%	+20.4%	-14.8%	-44.4%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-14.5%	-14.9%	+8.2%	-14.2%	-56.3%

Key facts CIK 1818331 CUSIP 81663L200 13F (30d) 11 filings 7 filers Visit website Investor relations

WGS · GeneDx Holdings Corp.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance